Tarsus Pharmaceuticals (TARS) Non Operating Investment Income (2023 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Non Operating Investment Income of -$6000.0 for Q2 2024, down 140.0% year-over-year from $15000.0 in Q3 2023, and down 101.43% quarter-over-quarter from $420000.0 in Q4 2023.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at -$6000.0 for Q2 2024.
- In Q2 2024, Non Operating Investment Income fell 140.0% year-over-year to -$6000.0; the TTM figure through Dec 2024 stood at $414000.0 (changed N/A YoY), while the FY2024 annual figure was -$591000.0, down 328.19% from the prior year.
- Non Operating Investment Income for Q2 2024 stood at -$6000.0, down from $420000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $420000.0 in Q4 2023, with the low at -$111000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 2.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.81 Mn |
| Jun 30, 2024 | -6,000.00 |
| Dec 31, 2023 | 420,000.00 |
| Sep 30, 2023 | -111,000.00 |
| Jun 30, 2023 | 15,000.00 |